![Graeme Fielder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Graeme Fielder
Director de Operaciones en AviadoBio Ltd. .
Cargos activos de Graeme Fielder
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AviadoBio Ltd.
![]() AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Director de Operaciones | 04/10/2022 | - |
Corporate Officer/Principal | 01/01/2020 | 04/10/2022 |
Historial de carrera de Graeme Fielder
Antiguos cargos conocidos de Graeme Fielder.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AUDENTES THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Formación de Graeme Fielder.
Auckland University | Doctorate Degree |
Stanford University | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 3 |
Reino Unido | 2 |
Nueva Zelanda | 2 |
Operativa
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
AviadoBio Ltd.
![]() AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Health Technology |
Astellas Gene Therapies, Inc.
![]() Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Graeme Fielder
- Experiencia